ArticleFrontiers in endocrinology2025
Immune checkpoint inhibitor-associated diabetes mellitus: the case series report.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real world incidence, predictors and outcomes of endocrine immune-related adverse events following immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2026Article
- Immune checkpoint inhibitor-associated diabetes mellitus: an overlooked immune-related adverse event-two case reports and a literature review.Frontiers in immunology · 2026Review
- Immune Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus: An Indian Case Series.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report aims to better define the rare adverse event of immune checkpoint inhibitor-associated diabetes mellitus(ICI-DM). We present 10 cases of patients including six of the patients had no prior history of diabetes, while four had varying degrees of pre-existing diabetes. Eight who received anti-PD-1 combination therapy, one who received anti-PD-1 monotherapy, and one who received dual anti-PD-1/CTLA-4 therapy. The mean time from initiation of immunotherapy to the onset of ICI-DM was 245.4 days (median, 149 days; range, 11 to 787 days). Diabetic ketoacidosis (DKA) occurred in 60% (6/10) of the patients, with a median fasting blood glucose level of 25.85 mmol/L (range, 14.76 to 38.23 mmol/L), and all had C-peptide levels below the normal range. Through a retrospective analysis of the clinical data of these 10 patients, we found that monitoring fasting blood glucose and HbA1c is crucial for patients undergoing or having undergone immunotherapy, as rapid pancreatic β-cell destruction can be observed in those who develop ICI-DM, potentially due to disruption of the PD-1/PD-L1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.